Monopar Therapeutics (MNPR) Stock: Buy, Sell, or Hold?
MNPR - Monopar Therapeutics Inc. Common Stock
$110.26
0.30 (0.27%)
▲
5d:
-6.99%
30d:
-4.04%
90d:
+86.58%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MNPR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MNPR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $110.26, which is considered oversold relative to its 30-day fair value range of $110.89 to $118.48.
Technical Outlook: Technically, MNPR is in a strong uptrend. Immediate support is located at $106.67, while resistance sits at $121.02.
Market Sentiment: MNPR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $126.31 (+14.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MNPR is in a strong uptrend. Immediate support is located at $106.67, while resistance sits at $121.02.
Market Sentiment: MNPR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $126.31 (+14.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$110.89 -
$118.48
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($126.31)
- CAUTION: 5-day price weakness (-7.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$110.89 -
$118.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$106.67
Resistance Level
$121.02
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-55.69
Wall Street Target
$126.31
(+14.6%)
Share & Embed Analysis
Last updated: September 13, 2026 3:26 AM ET
Data refreshes hourly during market hours. Next update: 4:26 AM
Data refreshes hourly during market hours. Next update: 4:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
